Loading clinical trials...

A Study of LY3841136 in Overweight and Obese Participants | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study of LY3841136 in Overweight and Obese Participants

A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants

NCT06345066•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female participants who are overtly healthy as determined by medical evaluation
•Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).
•Have clinical laboratory test results within normal reference range
•Have venous access sufficient to allow for blood sampling
•Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion Criteria

•Have type 1 or type 2 diabetes mellitus
•Have an abnormal 12-lead electrocardiogram (ECG)
•Have a history or presence of psychiatric disorders
•Have abnormal blood pressure and pulse rate
•Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.

Locations (3)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Fortrea Clinical Research Unit

Madison, Wisconsin, United States

Key Dates

Start Date

April 3, 2024

Primary Completion Date

September 29, 2025

Completion Date

September 29, 2025

Last Updated

October 15, 2025

Enrollment

ACTUAL participants

Conditions

ObesityOverweight

Interventions

Tirzepatide

DRUG

LY3841136

DRUG

Placebo

DRUG

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY3841136 in Overweight and Obese Participants

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss